Current concepts in intravitreal drug therapy for diabetic retinopathy

Saudi Journal of Ophthalmology

Volumn 24, Issue 4, 2010, Pages 143-149

  Pai, Anant ^a   El Shafei, Maha M ^a   Mohammed, Osman A Z ^a   Al Hashimi, Mustafa ^a  

^a HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

Anti VEGF drugs; Diabetic retinopathy; Intravitreal steroids

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; HYALURONIDASE; I VIATION; MICROPLASMIN; PEGAPTANIB; PLASMIN; POSIDUREX; RANIBIZUMAB; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; LASER THERMOTHERAPY; LOW DRUG DOSE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; VISUAL IMPAIRMENT;

EID: 77956612071     PISSN: 13194534     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjopt.2010.06.003     Document Type: Review

References (48)

1. Abdulla Walid, Fazwi Amani Anti-VEGF therapy in proliferative diabetic retinopathy. Int. Ophthalmol. Clin. 2009, 49:95-107.
2. Adamis A.P., Altaweel M., Bressler N.M., et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006, 113(1):23-28.
3. Aiello L.P. Angiogenic pathways in diabetic retinopathy. N. Engl. J. Med. 2005, 353:839-841.
4. Chen E., Park C.H. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006, 26:699-700.
5. Chew E.Y., Klein M.L., Ferris F.L., et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch. Ophthalmol. 1996, 114:1079-1084.
6. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008, 115(9):1447-1449. Diabetic Retinopathy Clinical Research Network.
7. Do D.V., Nguyen Q.D., Shah S.M., et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Br. J. Ophthalmol. 2009, 3:144-149.
8. Early photocoagulation for diabetic retinopathy. ETRDS Report Number 9. Ophthalmology 1991, 98:766-785. Early Treatment Diabetic Retinopathy Study Research Group.
9. Funatsu H., Yamashita H. Pathogenesis of diabetic retinopathy and the renin-angiotensin system. Ophthal. Physiol. Opt. 2003, 23(6):495-501.
10. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 2002, 99:11393-11398.
11. Ishikawa K., Honda S., Tsukahara Y., et al. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009, 23:108-111.
12. Jardeleza M.S.R., Miller J.W. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin. Ophthalmol. 2009, 24:87-92.
13. Jorge R., Costa R.A., Calucci D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006, 26:1006-1013.
14. Kang S.W., Sa H.S., Cho H.Y., Kim J.I. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch. Ophthalmol. 2006, 124(5):653-658.
15. Klein R., Klein B.E., Moss S.E. Visual impairment in diabetes. Ophthalmology 1984, 91:1-9.
16. Klein B.E., Moss S.E., Klein R., Surawicz T.S. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XIII: relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991, 98:1261-1265.
17. Klein R., Klein B.E., Moss S.E. The epidemiology of ocular problems in diabetes mellitus. Ocular Problems in Diabetes Mellitus 1991, 1-51. Blackwell Publications, Boston. S.S. Ferman (Ed.).
18. Klein R., Klein B.E.K., Moss S.E., et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long term incidence of macular edema. Ophthalmology 1995, 102:7-16.
19. Kuppermann B.D., Thomas E.L., de Smet M.D., et al. Vitrase for Vitreous Hemorrhage Study Groups. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol. 2005, 140(4):573-584.
20. Lam D.S., Chan C.K., Mohamed S., et al. Intravitreal triamcinoone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology 2007, 114(12):2162-2167.
21. Lyons T.J., Jenkins A.J., Zheng D., et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest. Ophthalmol. Vis. Sci. 2004, 45:910-918.
22. Maia O.O., Takahashi B.S., Costa R.A., et al. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am. J. Ophthalmol. 2009, 147(2):291-297.
23. Matthews D.R., Stratton I.M., Aldington S.J., Holman R.R., Kohner E.M. Risk of progression of retinopathy and visual loss related to tight control of blood pressure in Type 2 diabetes mellitus. UKPDS 69. Arch. Ophthalmol. 2004, 122(11):1631-1640.
24. Miljanovic B., Glynn R.J., Nathan D.M., Manson J.E., Schaumberg D.A. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 2004, 53:2883-2892.
25. Mirshahi A., Roohipoor R., Lashay A., et al. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur. J. Ophthalmol. 2008, 18:263-269.
26. Moradian S., Ahmadieh H., Malihi M., et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:1699-1705.
27. Moss S.E., Klein R., Klein B.E. The incidence of vision loss in a diabetic population. Ophthalmology 1988, 95:1340-1348.
28. Neelakshi Bhagat, Grigorian R.A., Tutela A., et al. Diabetic macular edema: pathogenesis and treatment. Surv. Ophthalmol. 2009, 54:1-32.
29. Nguyen Q.D., Shah S.M., Hafiz G., et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006, 113:1522.
30. Novak M.A., Rice T.A., Michels R.G., et al. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology 1984, 91:1485-1489.
31. Rizzo S., Genovesi-Ebert F., Di Bartolo E., et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:837-842.
32. Scanlon P.H. Prologue. Diabetic Retinopathy Management 2009, ix-xviii. Wiley-Blackwell, West Sessex. P.H. Scanlon, C.P. Wilkinson, S.J. Aldington, D.R. Mathews (Eds.).
33. Sheth H.G., Aslam S., Davies N. Lipid lowering drugs in diabetes: lipid lowering has ophthalmic benefits. Br. Med. J. 2006, 332(7552):1272-1273.
34. Silva P.S., Sun J.K., Aiello L.P. Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy. Semin. Ophthalmol. 2009, 24:93-99.
35. Spaide R.F., Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006, 26:275-278.
36. Stewart M.W., Rosenfeld P.J. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 2008, 92:667-668.
37. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993, 329(14):977-986. The Diabetes Control and Complications Trial Research Group.
38. Preliminary report on effects of photocoagulation therapy. Am. J. Ophthalmol. 1976, 81:383-396. The Diabetic Retinopathy Study Research Group.
39. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study findings. DRS Report Number 8. Ophthalmology 1981, 88:583-600. The Diabetic Retinopathy Study Research Group.
40. Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report Number 14. Int. Ophthalmol. Clin. 1987, 27:239-253. The Diabetic Retinopathy Study Research Group.
41. Photocoagulation for diabetic macular edema. The Early Treatment of Diabetic Retinopathy Study Report Number 1. Arch. Ophthalmol. 1985, 103:1796-1806. The Early Treatment of Diabetic Retinopathy Study Research Group.
42. Tonello M., Costa R.A., Almeida F.P., et al. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHistudy). Acta Ophthalmol. 2008, 86:385-389.
43. Tsilimbaris M.K., Pandeleondidis V., et al. Intravitreal combination of triamcinolone acetonide and bevacizumab (kenacort-avastin) in diffuse diabetic macular edeme. Semin. Ophthalmol. 2009, 24(6):225-230.
44. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
45. Wilkinson C.P., Ferris F.L., Klein R.E., et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003, 110:1677-1682.
46. Yang C.M., Yeh P.T., Yang C.H., et al. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am. J. Ophthalmol. 2008, 146:211-217.
47. Yeoh J., Williams C., Allen P., et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin. Exp. Ophthalmol. 2008, 36:449-454.
48. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetic epidemic. Nature 2001, 414:782-787.